• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    LSNE Acquires PSC Biotech’s Parenteral Mfg. Facility

    Financial Report: AbbVie

    Financial Report: West

    PAREXEL Appoints Chief Commercial Officer

    Interphex 2018: Video Highlights
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    LSNE Acquires PSC Biotech’s Parenteral Mfg. Facility

    Bristol-Myers Squibb Launches New Discovery Facility

    INTERPHEX: Antares Vision Explains LYO-CHECK Machine

    PCI Launches High Containment Packaging at Ireland Site

    ADC Bio Plans U.S. Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol-Myers Squibb Launches New Discovery Facility

    ADC Bio Plans U.S. Expansion

    Cambrex Continues Expansion Plans with New Lab

    Catalent Bolsters Drug Development Capabilities

    Q Therapeutics, REPROCELL Form MAGiQ Therapeutics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Legacy Pharmaceutical Packaging

    Fusion Scientific Laboratories

    Symbiosis Pharmaceutical Services

    Apex Graphics Inc.

    Avid Bioservices, Inc.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    AZ Restructures, To Build New HQ

    1,600 jobs to go, R&D to center in three locations

    Related CONTENT
    • AZ, MAP Pharmaceuticals Phase III Asthma Study Misses Endpoints
    • Xeloda Combo Approved for Early Colon Cancer
    • Financial Reports: Merck 2Q11
    • Orexo, AZ in Respiratory Research Pact
    • AZ: One Hire, Two Partnerships, More Layoffs
    03.18.13
    AstraZeneca will engage in a new restructuring plan, shedding 1,600 employees and relocating another 2,500 as it reorganizes its R&D structure and reduces its marketing staff over the next three years.
     
    Once the plan is enacted, AZ's small molecule and biologics R&D activities will be concentrated in three strategic centers: Cambridge, UK; Gaithersburg, MD; and Mölndal, Sweden. The locations were chosen due to their proximity to bioscience clusters, "making it easier to access world-class talent and opportunities for collaboration and partnerships," according to an AZ statement.
     
    AZ will invest approximately $500 million to establish a new, purpose-built facility in Cambridge, UK. The site will consolidate AZ's UK-based small molecule and biologics R&D. Cambridge will also become AZ new global corporate headquarters. Gaithersburg will become home to much of the company’s U.S.-based Global Medicines Development activities for small and large molecules and will accommodate some global marketing and U.S. specialty care commercial functions. That site contains MedImmune’s headquarters and is the primary location for AstraZeneca’s biologics activities. AZ's site in Mölndal, near Gothenburg, will continue to be a global centre for R&D, with a primary focus on small molecules.
     
    As a result of the restructuring, AZ will end R&D work at its Alderley Park, Cheshire, UK site, forcing a relocation of 1,600 employees to Cambridge, as well as the company’s nearby Macclesfield manufacturing facility or other AZ sites overseas. At least 700 non-R&D roles are expected to remain at Alderley Park.
     
    AZ's  Wilmington, DE site will lose approximately 1,200 employees, with a net gain of 300 in Gaithersburg. There will be an overall reduction of 650 positions in the U.S., with an additional 170 people to relocate to other AZ sites in the U.S. or overseas. Wilmington will remain the North America commercial headquarters, with 2,000 employees.
     
    In London, the majority of corporate and global commercial roles based there are expected to move to Cambridge, with some going to other sites. Following the transfer of the HQ to Cambridge, AZ's Paddington office will close by 2016. Currently, around 350 roles are based in London.
     
    In total, the moves will lead to 1,600 layoffs and the relocation of 2,500 employees from 2013 to 2016, at a cost of $1.4 billion, in addition to the $500 million expense of building the new HQ in Cambridge. Expected annual savings are around $190 million.
     
    Pascal Soriot, AZ's chief executive officer, remarked, “The changes we are proposing represent an exciting and important opportunity to put science at the heart of everything we do because our long-term success depends on improving R&D productivity and achieving scientific leadership. This is a major investment in the future of this company that will enable us to accelerate innovation by improving collaboration, reducing complexity and speeding up decision-making. The strategic centers will also allow us to tap into important bioscience hotspots providing more of our people with easy access to leading-edge academic and industry networks, scientific talent and valuable partnering opportunities.
     
    “I recognize that our plans will have a significant impact on many of our people and our stakeholders at the affected sites. We are fully committed to treating all our employees with respect and fairness as we navigate this important period of change.”
    Related Searches
    • R&D
    • Manufacturing
    • R&D
    • Development
    Suggested For You
    In vivo Models Targeting Respiratory Diseases In vivo Models Targeting Respiratory Diseases
    Heptares Gets $12mn AstraZeneca Milestone Heptares Gets $12mn AstraZeneca Milestone
    AstraZeneca, Heptares in Immuno-oncology Pact AstraZeneca, Heptares in Immuno-oncology Pact
    Sanofi, MedImmune in RSV Alliance Sanofi, MedImmune in RSV Alliance
    Financial Report: Lilly Financial Report: Lilly
    Valeant, AstraZeneca In Brodalumab Pact Valeant, AstraZeneca In Brodalumab Pact
    AstraZeneca To Build $285M Biologics Facility in Sweden AstraZeneca To Build $285M Biologics Facility in Sweden
    They Had Faces Then: Inversions and Pharma’s Identity Crisis They Had Faces Then: Inversions and Pharma’s Identity Crisis
    AZ Buys out Diabetes Partner BMS AZ Buys out Diabetes Partner BMS
    6	AstraZeneca, plc 6 AstraZeneca, plc
    AZ: One Hire, Two Partnerships, More Layoffs AZ: One Hire, Two Partnerships, More Layoffs
    Orexo, AZ in Respiratory Research Pact Orexo, AZ in Respiratory Research Pact
    Financial Reports: Merck 2Q11 Financial Reports: Merck 2Q11
    Xeloda Combo Approved for Early Colon Cancer Xeloda Combo Approved for Early Colon Cancer
    AZ, MAP Pharmaceuticals Phase III Asthma Study Misses Endpoints AZ, MAP Pharmaceuticals Phase III Asthma Study Misses Endpoints

    Related Breaking News

    • Analytical Services | Breaking News | Facilities | Industry News | R&D
      Cambrex Continues Expansion Plans with New Lab

      Cambrex Continues Expansion Plans with New Lab

      Completes $3.2M analytical research and development laboratory at its High Point, NC facility
      04.24.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

      Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

      To treat demyelinating and degenerative diseases of the CNS
      04.23.18

    • Bio News | Collaborations & Alliances | Drug Development | Formulation Development | Industry News | R&D
      Noramco, SPI Pharma Sign Agreement

      Noramco, SPI Pharma Sign Agreement

      To develop a set of “value-added” formulation packages for global pharma manufacturers of finished dosage forms
      04.23.18


    • Bio News | Facilities | Industry News | R&D
      Sterling Pharma Invests £6M To Expand Offerings

      Sterling Pharma Invests £6M To Expand Offerings

      For its pilot plant facility to enhance scale-up and small to midscale commercial API manufacturing capabilities
      04.19.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      ProBioGen, Tizona Therapeutics Enter Collaboration

      ProBioGen, Tizona Therapeutics Enter Collaboration

      To develop immune system centered treatments for cancer
      04.18.18

    • Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Telix, INSERM, and ARRONAX Enter Agreement

      Telix, INSERM, and ARRONAX Enter Agreement

      To explore the feasibility of using several of Telix's clinical targeting agents with astatine
      04.16.18


    • Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Idera, Pillar Partners Enter Agreement

      Idera, Pillar Partners Enter Agreement

      Pillar Partners will provide funding to support three clinical trials to expand the clinical research of Idera's IMO-2125
      04.16.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Kineta, Genentech Enter Collaboration

      Kineta, Genentech Enter Collaboration

      To develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain
      04.16.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      GSK, Orchard Therapeutics Enter Strategic Agreement

      GSK, Orchard Therapeutics Enter Strategic Agreement

      GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard
      04.12.18


    • Analytical Services | Bio News | Collaborations & Alliances | Industry News | R&D
      Symcel, Karolinska Institutet Enter Partnership

      Symcel, Karolinska Institutet Enter Partnership

      For the evaluation of calScreener technology as an improved method to test for combinations of antibiotics in sepsis patients
      04.11.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Zealand, Roche Diabetes Care Enter Collaboration

      Zealand, Roche Diabetes Care Enter Collaboration

      For the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI)
      04.11.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Inovio, CEPI Enter Partnership

      Inovio, CEPI Enter Partnership

      Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome
      04.11.18

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Novartis Inks $8.7B Deal to Acquire AveXis

      Novartis Inks $8.7B Deal to Acquire AveXis

      Novartis will pay $218 a share of AveXis in cash, an 88% premium to its closing price on April 6
      04.10.18

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Methods Development | R&D
      Wave Life Sciences, Deep Genomics Enter Collaboration

      Wave Life Sciences, Deep Genomics Enter Collaboration

      To identify novel therapies to be developed by Wave for the treatment of genetic neuromuscular disorders.
      04.10.18

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Promethera Biosciences Acquires Baliopharm

      Promethera Biosciences Acquires Baliopharm

      Promethera will now have control over Baliopharm’s entire antibody development programs
      04.10.18

    Breaking News
    • LSNE Acquires PSC Biotech’s Parenteral Mfg. Facility
    • Financial Report: AbbVie
    • Financial Report: West
    • PAREXEL Appoints Chief Commercial Officer
    • Interphex 2018: Video Highlights
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.